CA
NZ
UK
AU
IND
US
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B)based in Sweden, focuses on research and development of therapies aimed at neurodegenerative diseases. The company previously partnered with Eisai on the development of Leqembi® (lecanemab), an approved treatment for early Alzheimer’s disease. Beyond Alzheimer’s, BioArctic is pursuing …
Moderna, Inc. (NASDAQ: MRNA)based in Cambridge, Massachusetts, develops mRNA-based vaccines and therapeutics for infectious diseases, cancer, rare conditions, and autoimmune disorders.
BeOne Medicines Ltd. (NASDAQ:ONC)has announced that the U.S. Food and Drug Administration (FDA) has approved a tablet version of its BTK inhibitor BRUKINSA® (zanubrutinib). The tablet formulation is approved for use across all five existing indications in the United States.
Guided Therapeutics, Inc.is a medical device company developing non-invasive diagnostic platforms based on biophotonic technology. Its first product, the LuViva® Advanced Cervical Scan, is used for real-time screening of cervical disease at the point of care. Headquartered in the United States, the company collaborates …
HSBC has upgraded Dr Reddy’s Laboratories (NYSE:RDY) American Depositary Receipts (ADRs) fromHoldtoBuy, lifting its price target from USD 14.44 to USD 16.90. The move follows a revised outlook that anticipates a revenue boost from semaglutide, a generic alternative to Novo Nordisk’s high-demand weight-loss and …
Corcept Therapeutics Incorporated (NASDAQ: CORT)is a commercial-stage biopharmaceutical company headquartered in the United States. It focuses on discovering and developing therapies that modulate the effects of cortisol to treat a variety of serious disorders in endocrinology, oncology, metabolism, and neurology.
On June 4, 2025, HC Wainwright & Co. upgraded its rating for Agenus (NasdaqCM: AGEN) fromNeutraltoBuy, reflecting a change in analyst sentiment. The firm’s updated outlook comes as the average one-year price target for the clinical-stage immuno-oncology company rises to USD 6.46 per share, …
On June 4, 2025, HC Wainwright & Co. upgraded AnaptysBio (NasdaqGS:ANAB) fromNeutraltoBuy, signaling a shift in sentiment around the biotechnology company. The change follows updated analyst projections that suggest a significant upside potential based on the current share price.
On Tuesday,Morgan Stanley (NYSE:MS)upgradedKymera Therapeutics (NASDAQ:KYMR)fromEqualweighttoOverweight, raising its price target toUSD79fromUSD49. The move reflects growing interest in the clinical progress of Kymera's drug pipeline, particularly its STAT6-targeting therapy KT-621.
The Ensign Group, Inc. (Nasdaq: ENSG) announced the acquisition of operations at three skilled nursing facilities, adding 232 licensed beds to its portfolio. The acquisitions include Ironwood Rehabilitation and Care Center (80 beds) and Lakeside Rehabilitation and Care Center (100 beds), both located in …
Please wait processing your request...